Piper Sandler Maintains Overweight on Perspective Therapeutics, Lowers Price Target to $14

Benzinga Newsdesk www.benzinga.com Negative 71.1%

Neg 71.1% Neu 0% Pos 0%

Piper Sandler analyst Biren Amin maintains Perspective Therapeutics (AMEX:CATX) with a Overweight and lowers the price target from $16 to $14.